Ivantis' eyelash-sized eye stent helped lower intraocular pressure in patients who have undergone cataract surgery after one year, data that could help the company convince the FDA of its device's ...

The Hydrus stent is 8 mm long. In comparison, ... The iStent has given surgeons and patients another alternative, with no more risk to the eye than cataract surgery, Wiley said.

Eyes that were treated with the Hydrus microstent, which is designed to lower eye pressure, were less likely than untreated eyes to need subsequent invasive glaucoma surgery (6.4% vs 2.5%; P=0.022 ...

The HORIZON trial, which compared cataract surgery alone with cataract surgery in conjunction with implantation of the Hydrus Microstent (Ivantis, Inc; Irvine, California), concluded at 3 years ...

NEW ORLEANS — Two-year results of the HORIZON study show that 77.2% of patients implanted with a Hydrus microstent achieved the primary endpoint of a 20% reduction in washed-out IOP compared ...

“HYDRUS II is the first randomized, controlled, multicenter trial to demonstrate the ability of a MIGS device to lower IOP (> 20% without meds) compared to cataract surgery alone at two years.

RELATED: Alcon pulls eye micro-stent from market after new 5-year safety data The FDA’s approval for the Hydrus device came the same month Alcon began a voluntary recall of all versions of its ...

June 25, 2012 — The US Food and Drug Administration (FDA) has approved the first stent for use in cataract surgery to reduce intraocular eye pressure in adult patients with mild or moderate open ...

Over a 5-year period, the annual rate of progression in vision loss averaged 0.49 dB with surgery alone, compared with 0.26 dB with surgery plus a Schlemm's canal microstent (Hydrus). The results ...